Supposedly
this is peer reviewed for appearing in "Trends in Internal Medicine", which claims to be "
an international, open-access peer-reviewed, journal".
Technically, Pfizer's phase 3 clinical trial hasn't been fully peer-reviewed yet as it's still ongoing --
completion date: May 2, 2023.
It seems Pfizer have completed the primary efficacy endpoint but not the safety endpoint:
I don't understand why FDA didn't leave it under EUA until phase 3 is complete.
Pfizer has shown their product reduces Covid hospitalisations (but not necessarily
all-cause hospitalisations). This is counterintuitive because if it reduces hospitalisation, and hospitalisation correlates to mortality, then shouldn't it reduce mortality as well?
Apparently Pfizer are working on an
antiviral drug which may use similar mechanism to IVM.